Rhythm Pharmaceuticals ( (RYTM) ) has released its Q2 earnings. Here is a breakdown of the information Rhythm Pharmaceuticals presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing treatments for rare neuroendocrine diseases, with its lead product, IMCIVREE, targeting obesity due to genetic disorders.
In its second quarter of 2025, Rhythm Pharmaceuticals reported significant growth in global sales of IMCIVREE, with net product revenue reaching $48.5 million, marking a 29% increase from the previous quarter. The company also highlighted progress in its clinical trials and regulatory submissions for setmelanotide, aimed at treating acquired hypothalamic obesity.
Key financial metrics for the quarter included a net loss of $48 million, an increase from the previous year’s $33.6 million loss, attributed to higher research and development expenses and increased selling, general, and administrative costs. The company successfully raised approximately $189.2 million through a public offering, strengthening its financial position. Clinical highlights included successful Phase 2 trial results for bivamelagon and ongoing regulatory submissions for setmelanotide in the U.S. and EU.
Looking ahead, Rhythm Pharmaceuticals remains focused on expanding the reach of setmelanotide into additional rare diseases and advancing its clinical pipeline. The company is optimistic about its financial and operational outlook, supported by its strengthened balance sheet and ongoing clinical developments.